Christopher Herrem

Christopher Herrem is the Head of Medical Affairs Strategy for Rheumatology at UCB, a role they have held since 2024. They have a strong background as a Medical Director, with prior positions at Mylan and Novartis focusing on rheumatology. Christopher's expertise encompasses biologics and autoimmune diseases, bolstered by experience in various leadership roles at UCB, including Associate Director and Senior Scientific Director. They earned a Ph.D. in Immunology from the University of Pittsburgh School of Medicine and hold a B.S. in Genetics from the University of Wisconsin-Madison.